covaxin

Bharat Biotech’s Covaxin gets drug regulator approval for 6-12 year olds

Bharat Biotech’s Covaxin gets drug regulator approval for 6-12 year olds

The Drugs Controller General of India (DCGI) has given Bharat Biotech's Covid vaccine Covaxin restricted emergency use authorisation for children between the age of 6-12 years. Cadila Health's ZyCoV-D has received restricted emergency use authorisation for children above the age of 12 years of age. ET had reported that the subject expert committee ( SEC) of the Drugs Controller General of India recommended the use of Bharat Biotech's Covaxin among children aged 6-12 years amid an uptick in cases in schools. Covaxin, one of the main vaccines administered to adults, is currently being administered to children in the age group…
Read More
Mixing and matching of Covaxin and Covishield vaccines show better result: ICMR

Mixing and matching of Covaxin and Covishield vaccines show better result: ICMR

Mixing and matching of Covaxin and Covishield, the Covid-19 vaccines available in India, have shown better results in building immunity against the virus, according to a study by the Indian Council of Medical Research (ICMR). The study was conducted between May and June this year in Uttar Pradesh. The study suggests that immunisation with combination of an adenovirus vector platform-based vaccine followed by inactivated whole virus vaccine was not only safe but also gave better immunity against the variant strains of SARS-CoV-2. "Such mixed regimens will also help to overcome the challenges of shortfall of particular vaccines and remove hesitancy…
Read More
Centre caps 20% of Covaxin supply for first dose beneficiaries, via CoWIN

Centre caps 20% of Covaxin supply for first dose beneficiaries, via CoWIN

Easing the restriction over immunisation by Bharat Biotech’s Covid-19 vaccine Covaxin, the central government has now allowed the vaccination centres to administer the vaccine’s first dose to all the age group although with a cap of 20 per cent. As per the officials, the capping of 20 per cent is in place considering the limited supply of Covaxin. “The government vaccination centres may restart administration of the first dose of Covaxin. However, considering the limited vaccine supply, to begin with, the first dose slots may be limited to up to 20% of the total session capacity,” the order read. The…
Read More
Covaxin to get WHO nod soon? Chief scientist says Covid-19 vaccine trial data ‘looks good’

Covaxin to get WHO nod soon? Chief scientist says Covid-19 vaccine trial data ‘looks good’

WHO Chief Scientist Dr Soumya Swaminathan on Thursday said data on Bharat Biotech’s vaccine Covaxin looks good. As Covaxin awaits WHO approval, Swaminathan said the pre-submission meeting was held on June 23 and the data packet is being assembled. The Phase-3 trial data looks good, they’ve looked at the variants too, she said in an interview to CNBC-TV18. “The overall efficacy is quite high. The vaccine efficacy against the Delta variant is low but it is still quite good," she said. The safety profile so far meets the WHO benchmarks, the scientist said. “We keep a close eye on all…
Read More
Congress leader makes sensational claims about Covaxin

Congress leader makes sensational claims about Covaxin

On Tuesday, Congress leader Gaurav Pandhi made some controversial claims about the component of Bharat Biotech and ICMR's Covaxin. Sharing an RTI document on his Twitter account, the Congress leader claimed that Covaxin contains the serum of a newborn calf. His claims were based on an RTI response from the Central Drugs Controller General to Vikas Patni, the man who filed the query. Gaurav Pandhi wrtes, "In an RTI response, the Modi Govt has admitted that Covaxin consists newborn calf serum .....which is a portion of clotted blood obtained from less than 20 days young cow-calves, after slaughtering them. THIS…
Read More
Tamil Nadu runs out of stock, halts vaccination

Tamil Nadu runs out of stock, halts vaccination

Vaccination in Tamil Nadu has come to a grinding halt as several districts have fallen short of the required doses in the state. 39 out of the 45 health units of the state reported a shortage of vaccines. The state is expecting 63,370 doses of Covaxin on Wednesday and another 40,000 doses on Thursday. A quantity of 3.6 lakh doses of Covishield vaccine is to be received by the state on Friday and health experts feel only after these arrivals would things get back on track. On Tuesday, Virudhanagar MP and Congress leader B. Manickam Tagore refused to take his…
Read More
AIIMS Delhi starts screening of children for Covaxin trials

AIIMS Delhi starts screening of children for Covaxin trials

The trial on children has already started at AIIMS Patna to see if the Bharat Biotech jab is suitable for children. Participants would be given the vaccine after their screening report comes.The trial is to be conducted on 525 healthy volunteers. In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28. “The screening of children for conducting trial of Covaxin has started. Participants would be given the vaccine after their screening reports come,” Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS, said. India’s drug regulator had…
Read More
India looks forward to WHO’s approval for Covaxin: Foreign Secretary

India looks forward to WHO’s approval for Covaxin: Foreign Secretary

India is looking forward to the WHO’s approval for its indigenous Covid-19 vaccine manufactured by Bharat Biotech and is in talks with major vaccine manufacturers like Pfizer, Johnson & Johnson, and Moderna about sourcing and possible local manufacture of their jabs in India, Foreign Secretary Harsh Vardhan Shringla said today. Hyderabad-based Bharat Biotech has applied to the WTO for the Emergency Use Listing (EUL) of its vaccine candidate Covaxin. However, the WHO has sought “more information” from Bharat Biotech on its EUL application. Addressing the WHO’s “South-East Asia Regional Health Partners’ Forum on Covid-19”, Shringla also stated that India was…
Read More
Bharat Biotech has refused to supply doses to Delhi “under government instructions”

Bharat Biotech has refused to supply doses to Delhi “under government instructions”

Covaxin maker Bharat Biotech has refused to supply doses to Delhi "under instructions" from the central government, Deputy Chief Minister Manish Sisodia alleged today, accusing the Centre of controlling the supply of Covid shots and of "vaccine mismanagement". The company said it was "disheartening" that some states were complaining about its intentions. Bharat Biotech has said it will not be able to supply vaccines to the capital citing directives of the government and limited availability, Mr Sisodia said at a digital press meet. "The Covaxin manufacturer has, in a letter, said it cannot provide Delhi government vaccines due to unavailability,…
Read More

Bharat Biotech has been supplying Covaxin directly to 14 states

Bharat Biotech, Hyderabad based vaccine manufacturer has been supplying its COVID-19 vaccine ‘Covaxin’ directly to 14 states beginning May 1. In a tweet joint managing director of Bharat Biotech Suchitra Ella said, “Glad to announce that Bharat Biotech confirms direct supply of COVAXIN to some state government since 1st May 2021, based on the allocation received by the GoI”. Here the 14 state includes Andhra Pradesh, Assam, Chhattisgarh, Gujarat, Jammu & Kashmir, Jharkhand, Madhva Pradesh, Odhisha, Tamil Nadu, Telangana, Uttar Pradesh and West Bengal.  Previously the vaccine was distributed only for those above 45 years and all the frontline warriors…
Read More